Roche has obtained CE mark for its cobas SARS-CoV-2 Qualitative test for the use of saliva samples to detect SARS-CoV-2.
The non-invasive test runs on the fully automated cobas 6800/8800 systems and is intended for use by both asymptomatic and symptomatic people.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is a real-time RT-PCR test which is designed to detect nucleic acids from SARS-CoV-2 in nasal swab and saliva specimens.
Following a healthcare professionals’ instructions, individuals with or without symptoms have the option to self-collect their saliva samples on site.
According to the company, saliva sample collection is a non-invasive, easy, and convenient testing approach for patients to easily collect their own samples.
This sample collection method reduces physical contact and helps to decrease the exposure risk for healthcare professionals to the virus.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRoche Diagnostics Solutions Molecular Labs head Cindy Perettie said: “One of the key strategies to reduce Covid-19 transmission is to stop the silent spread of the disease early.
“Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people. This is crucial for public health and keeping our communities safe.”
The company stated that the cobas SARS-CoV-2 Qualitative test has already been available for use with nasopharyngeal, oropharyngeal swabs, and nasal samples collected by a healthcare professional.
In November this year, Roche introduced cobas 5800 system, a new molecular diagnostics system, in countries accepting the CE mark.
The new system delivers integration, automation consolidation and standardisation, and enables laboratories to consolidate more than 90% of testing on a single platform.
